Mutagen treatment of mouse P815 tumor cells produces tum-variants that are rejected by syngeneic mice because these variants express new surface antigens. These "tum antigens" are recognized by cytolytic T lymphocytes but induce no detectable antibody response. Transfection of P815 cell line P1.HTR with DNA of tum-variant P91 yielded transfectants expressing tum antigen P91A. They were detected by their ability to stimulate proliferation of cytolytic T lymphocytes [Wolfel, T., Van Pel, A., De Plaen, E., Lurquin, C., Maryanski, J. L. & Boon, T. (1987) Immunogenetics 26, [178][179][180][181][182][183][184][185][186][187]. A cosmid library of a cell line expressing antigen P91A was transfected into P1.HTR. Transfectants expressing the antigen were obtained. By packaging directly the DNA of a transfectant with A phage extracts, we obtained a small cosmid population containing as major component a cosmid that transferred the expression of P91A. The assay of various restriction fragments of this cosmid led to the isolation of an 800-base-pair fragment containing the P91A sequence required for transfection. Comparison with a homologous cDNA showed that this fragment contained only one of the several exons of the P91A gene. The normal and the tumforms of the gene differ by one nucleotide located in this 137-base-pair exon. The essential role of this mutation, which produces an amino acid change, was confirmed by site-directed mutagenesis. No significant sequence similarity was found between the 800-base-pair fragment and any recorded gene.
In vitro mutagen treatment of mouse tumor cell lines generates at high frequency immunogenic variants that are rejected by syngeneic mice (1) . Since they fail to form tumors, these stable variants have been named "tum-" as opposed to the original "tumr+" cell, which forms progressive tumors. Most tum-variants express transplantation antigens not found on the tum+ cell. The existence of these "tumantigens" can be demonstrated in vivo by cross-immunization experiments or in vitro with cytolytic T lymphocytes (CTLs) (2) .
We have studied a series of tum-variants derived from mastocytoma P815, a tumor induced iq a DBA/2 mouse with methylcholanthrene (3) . For most P815 tum-variants, stable CTL clones have been obtained that show a strict specificity for the immunizing variant and thus define one or several tum-antigens (4) . Despite numerous attempts, we failed to obtain antibodies against these variaqt-specific antigens.
The diversity of tum-antigens is considerable: the analysis of 15 P815 tum-variants demonstrated the existence of a different antigen on each of them (5) . To understand the underlying genetic mechanism, we undertook the cloning of the "tum-genes" that determine the expression of tumantigens. As a first step, we attempted DNA-mediated transfer of antigen P91A, one of the two tum-antigens of P815 variant P91. Other workers have described the production of transfectants for surface antigens (6, 7) , but in these instances, the antigen-expressing transfectants were detected with antibodies. For tum-antigens, we had to develop procedures ensuring detection with CTLs. This required a DNA-recipient cell line that was of H-2d haplotype like P815 and that showed good sensitivity to CTL lysis. The P815 tum+ clonal line P1 fulfilled those requirements but proved unsuitable because of its very low transfection efficiency. Fortunately, a highly transfectable P815 cell, P1.HTR, could be selected by repeated transfection cycles (8) . We (12) .
Transfection. Transfections were performed on P1.HTR by the calcium phosphate precipitation method, as described (9) . For the transfection of the c2RB cosmid library, groups of 5 x 106 P1.HTR cells were treated with 60 ,ug of DNA of the amplified library and 2 kug of cosmid pHMR272 (13) . Transfectants were selected with hygromycin B (350 tg/ml).
For transfection with isolated plasmids, cells were treated with 10 ,g of DNA and 2 jig of pSVtk-neop (14) and selected with neomycin analog G418 (1.5 mg/ml).
The detection of transfectants expressing antigen P91A was described before (9) . In brief, antibiotic-resistant transfectants were divided in microcultures of 30 cells. When they had grown to 6 x 104 cells, they were duplicated and 500 cells from CTL clone CTL-P91:6 were added. Stimulation was ascertained 5 days later by visual observation of CTL proliferation and by measuring the specific lytic activity of the CTL content of every microculture. The duplicates of positive microcultures were subcloned and cells expressing the P91A antigen were identified by visual observation of their lysis by CTL-P91:6 (9). Positive clones were confirmed by assay of chromium release from 51Cr-loaded cells.
Cosmid Rescue. For direct packaging, high molecular weight DNA of transfectants was packaged in Gigapack extracts. Infection of ED8767 and selection of Ampr colonies were as above.
For rescue with cosmid arms of pTL6, the two types of arms of pTL6 (15) were prepared by digestion with either Pvu II or BstEII, treatment with phosphatase, and digestion with Bgl II. DNA of transfectants was partially digested with Mbo I and fragments of 50-100 kb were prepared by centrifugation (11) . Cosmid arms (1.5 ,g) were mixed with 1.5 ,ug of insert DNA. After ligation, packaging, and infection of ED8767, Tetr or Ampr colonies were selected to recover the cosmids obtained with BstEII arms and Pvu II arms, respectively (see Fig. 2 ).
cDNA Libraries. Total cellular RNA was purified by the LiCl/urea method (16) . cDNA libraries in bacteriophage AgtlO were prepared as described (17) . (10) . High molecular weight DNA of P91.-T6.T1, a secondary transfectant that expresses antigen P91A, was partially digested with Mbo I and 40-to 50-kb fragments were ligated to the BamHI site of c2RB cosmid arms. The library was divided into 19 groups of 35,000 independent cosmids. Each group was considerably amplified and DNA was extracted. In the amplified population, 60% of the cosmids had retained inserts of more than 35 kb, whereas the others had lost them.
DNA from each cosmid group was cotransfected into P1.HTR with pHMR272, which confers resistance to hygromycin B (HmB) (13) . Approximately 3000 HmBr transfectants per group were tested for their ability to stimulate proliferation of an anti-P91A CTL clone, and the positive transfectants were confirmed by a lytic assay as described (9) . Two of the 19 cosmid groups produced transfectants expressing P91A. Group 7 produced one P91A transfectant (P91.TC7.1) out of 3000 HmBr transfectants. When group 2 proved positive, additional cells were transfected, so that three P91A transfectants P91.TC2.1, -2, and -3 were obtained from a total of 10,000 HmBr cells. A Southern blot (19) performed with the DNA of the four transfectants expressing P91A showed that they had integrated a number of cosmids ranging from 6 to more than 30.
Rescue of a Cosmid Transferring the Expression of Antigen P91A. Lau and Kan (20) reported that a cosmid containing a globin gene, which had been used to obtain transfectants, could be recovered by packaging directly the DNA of these transfectants into A phage heads. Presumably, this was made possible by occasional tandem integration of two cosmids producing a pair of cos sites that are separated by 39-52 kb of DNA, the size that can be packaged in A phage heads. By packaging 1 ,ug of DNA of transfectant P91.TC2.1, we obtained about 240 cosmid colonies selected with the Ampr marker of c2RB (Table 1) . Cosmid DNA was prepared from 16 colonies. Nine of these produced the same 37-kb cosmid, C91.2.1. When it was cotransfected into P1.HTR cells with pSVtk-neof3, 80% of the Neor transfectants were found to express antigen P91A (Table 2 ). Direct packaging of the DNA of P91.TC2.3 and P91.TC7.1 produced several thousand cosmids per microgram of DNA, a number in line with the higher number of cosmids integrated in these transfectants (Table 1) . However, no transfectant expressing antigen P91A was obtained with these cosmids. In agreement with this negative result, no positive colony was identified when these cosmids were hybridized later with the BamHI-Pvu II fragment of cosmid C91.2.1 (Fig. 3) .
The success of the "direct packaging" with the DNA of some but not all transfectants was anticipated, since one does not expect every transfected tum-gene to be inte- (Fig. 3) . These two fragments overlap by only 3.9 kb; the essential tum-sequence must be located in this overlap region. Expression of P91A could indeed be transfected by the 3.9-kb BamHI-HindIII fragment. This fragment could be reduced further to a 1.75-kb and even to a 0.8-kb fragment that transferred the expression of the antigen (Fig. 3) .
Structure of the 0.8-kb P91A Fragment. The sequence of the 0.8-kb Pst I-Pvu II fragment that transfers the expression of P91A is shown in Fig. 4 . The exon/intron structure of the fragment was determined by comparing its sequence to that of homologous cDNA regions. cDNA libraries were derived with the AgtlO system (17) from P1 and from P91.
They were screened by hybridization with the 1.75-kb Bam-HI-Pvu II fragment of C91.2.1. A few positive P1 and P91 cDNA clones were obtained. By comparison with their sequence, we located on the genomic 0.8-kb fragment a single exon of 137 base pairs, bounded by consensus splice acceptor and donor sequences. Only one reading frame can be read through the entire exon. The corresponding amino acid sequence is shown in Fig. 4 .
The hybridization pattern of several cDNA clones with various restriction fragments of cosmid C91.2.1 indicated that gene P91A is longer than 8 kb and contains several exons located both before and after the exon of the 0.8-kb fragment.
A single band of intensity corresponding to one copy was seen on Southern blots of EcoRI-digested P815 DNA hybridized with the 0.8-kb P91A fragment, even in low-stringency salt and temperature conditions. A computer searcht failed to reveal sequence similarity between this fragment and recorded mouse or human gene sequences. The search was done using the FASTN program, with a K-tuple parameter of 3 and of 6 (21) .
Presence of a Mutation in the P91A tum-Gene. To compare the sequence of the 0.8-kb transfecting fragment of the P91A gene with that of its normal homolog, we prepared a cosmid library from tum+ cell line P1, which does not express antigen P91A. Approximately 700,000 cosmids were screened by hybridization with the 1.75-kb BamHI-Pvu II fragment of cosmid C91.2.1. Four positive cosmids were identified. From one of those (C1.91A.1), we isolated a 3.9-kb BamHI-HindIII fragment and a 0.8-kb Pst I-Pvu II subfragment that were clearly homologous to the transfecting fragments of C91.2.1. As expected, transfection with the fragments of P1 origin did not produce cells expressing antigen P91A (Table 2) .
The sequence of the normal 0.8-kb fragment was found to differ from the P91A tum-fragment by only a single nucleotide located in the exon: a guanine residue in the normal gene is replaced by an adenine in the tum -sequence at position 274 (Fig. 4) . This transition corresponds to an amino acid change from arginine to histidine. To confirm that this mutation was sufficient to cause the expression of antigen P91A, we carried out site-directed mutagenesis on the 0.8-kb fragment of P1 origin cloned in M13 with an oligonucleotide representing the mutant sequence centered around position 274 (18) . Phages were obtained that had acquired the tummutation and others that had kept the normal sequence, as seen by differential hybridization with oligonucleotides carrying either the normal or the mutant sequence. M13.mut.2, which was sequenced to verify that it carried the tummutation (adenine in position 274), transferred the expression of antigen P91A (Table 2) Blot hybridization was performed with mRNA from both P1 and P91 cells. Hybridization with the 1.75-kb Bam-HI-Pvu II fragment of gene P91A revealed a unique 2.2-kb band of similar intensity on the blots of both P1 and P91 origin (data not shown). The expression of tum-antigen P91A results therefore from a point mutation occurring on a protein that is already expressed in the original tum+ cell.
DISCUSSION
Cosmid transfection and rescue combined with detection of antigen-expressing transfectants by CTL stimulation enabled us to clone the gene that determines the expression of tum-antigen P91A. Preliminary results suggest that these procedures will ensure the cloning of other tum -genes. We hope that they will also lead to the isolation of the genes of other transplantation antigens that are recognized by T cells but do not induce an antibody response. Most tumorassociated transplantation antigens, male-specific antigen H-Y, and minor histocompatibility antigens belong to this category (22) .
Our approach was facilitated by the ability of small fragments of the P91A gene to transfer the expression of the antigen, as this lifted the requirement that the rescued cosmid must carry the entire gene. How this comes about is presently unclear. The 0.8-kb fragment appears to lack the transcriptional control sequences that could ensure autonomous expression. Possibly, some fragments integrate during transfection close to a promoter, so that a peptide encoded by the exon is produced. The recent work of Townsend et al. (23) on influenza antigens suggests that such a small peptide or part of it could associate with a class I histocompatibiiity molecule so as to be recognized by CTLs. An alternative possibility is that some of the transfected fragments engage in homologous recombination with the normal gene present in the recipient cell. This has been reported, but with much lower frequencies than those we observe (24) . We cannot explain our high frequency by the presence of a large number of homologous genes, since the 0.8-kb P91A fragment hybridizes with a single band on Southern blots.
Our results begin to clarify the genetic nature of tumvariants. One paradox concerning these stable variants was their exceptionally high frequency: 1-20% in tumor cell populations reduced to 1% survival by mutagen treatment (5) . This led us to consider the possibility that tum-variants arise through the expression of a gene that is normally silent. For tum -antigen P91A, this hypothesis is clearly ruled out by our results. The P91A gene of tum-variant P91 has undergone a point mutation, and the single mRNA species that hybridizes with the transfecting P91A sequence is also produced by the original P1 tum+ cell. We therefore conclude that a protein that is already expressed in the tum+ cell undergoes a structural change that results in the expression of a strong antigen recognized by CTLs. The simplest interpretation of our results is that we have isolated the structural gene for the P91A antigen. The recent work with influenza peptides (23) suggests a way of obtaining direct proof of the role of the P91A exon that contains the tummutation: evaluation of the ability of synthetic peptides corresponding to the region surrounding the mutation to render P1 cells sensitive to lytic attack by anti-P91A CTLs.
The relevance of the tum-antigens defined with CTLs to the rejection of tum-variants is amply demonstrated by two sets of observations. First, when variants that had lost their tum -antigen were selected in vitro with the appropriate CTLs, we observed that these antigen-loss variants had regained their ability to form tumors (25) . Second, when we analyzed in vitro the cells of the rare progressive tumors that were obtained after injection of tum-variants, we found that they had lost tum -antigens. This was observed with antigen P91A (26) . Moreover, we observed recently that P1 cells expressing antigen P91A after transfection with the P91A sequence produce tumors after considerably longer delay than that observed with the original P1 cells, even though the transfected cells expressed only one of the two tum-antigens of P91 (unpublished data).
The relation between P91A and genes of the major histocompatibility complex (H-2, in the mouse) deserved careful examination, because tumor-specific antigens of a UV-induced tumor were found to be H-2 class I variant molecules (27) . It appears unlikely that P91A is related to H-2 because, in addition to the lack of sequence homology, the length of the mutated P91A exon is very different from that of the exons coding for external domains of class I and class II H-2 molecules. Structural data reported for tumor-specific antigens of tumor Meth A (28, 29) show no sequence homology with our P91A fragment.
It is of course impossible to predict that the mutational origin of tum-antigen P91A will also apply to other tumantigens. However, on the basis of the present evidence, it appears reasonable to adopt the term tum-mutants rather than tum-variants.
